According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “
Separately, ValuEngine upgraded shares of CHF Solutions from a hold rating to a buy rating in a report on Tuesday, December 3rd.
CHF Solutions (NASDAQ:CHFS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.41) by ($0.29). CHF Solutions had a negative return on equity of 229.50% and a negative net margin of 317.60%. The firm had revenue of $1.25 million for the quarter. As a group, analysts anticipate that CHF Solutions will post -6.45 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. A.R.T. Advisors LLC purchased a new stake in shares of CHF Solutions in the second quarter valued at $34,000. Virtu Financial LLC bought a new stake in shares of CHF Solutions in the 3rd quarter worth about $48,000. Finally, Anson Funds Management LP purchased a new position in shares of CHF Solutions during the 2nd quarter worth about $278,000. 9.43% of the stock is owned by institutional investors.
About CHF Solutions
CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
See Also: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.